文献速递前列腺癌

澳大利亚与新西兰局限性前列腺癌治疗差异:注册研究

Treatment variations in localised prostate cancer in Australia and New Zealand: a registry study.
PubMed 文献 · BJU Int · 2025-08-22

基于PCOR-ANZ注册数据库2015-2018年36 504例局限性前列腺癌患者,分析治疗模式及相关因素。结果显示中危占49.2%、根治性前列腺切除占40.3%,低危多无主动治疗(81.5%);低社会经济地位与地区/公立医院诊断者接受非手术治疗的几率更高,且独立于年龄与疾病风险。

要点

  • 中危患者占49.2%,根治性前列腺切除是最常见治疗(40.3%)。
  • 低危患者多数(81.5%)接受无主动治疗。
  • 低社会经济地位者无主动治疗、放疗、ADT及ADT+放疗的OR分别为1.84、1.53、2.66、2.56。

核心结论

  • 社会经济地位和医院提供者因素与局限性前列腺癌治疗选择相关,且独立于年龄或疾病风险分类。

研究设计与样本

  • 基于PCOR-ANZ数据库的注册研究,纳入2015-2018年新西兰和澳大利亚七个司法管辖区的36 504例患者。
  • 采用多分类逻辑回归分析与根治性前列腺切除相比,接受无主动治疗、放疗、ADT及ADT+放疗的可能性因素。

主要发现

  • 最常见风险组为 intermediate-risk(49.2%),最常见治疗为根治性前列腺切除(40.3%)。
  • 低危患者多数接受无主动治疗(81.5%)。
  • 与根治性前列腺切除相比,地区居民、低社会经济地位地区居民及地区或公立医院诊断者接受其他治疗的几率更高。
  • 最低社会经济地位组无主动治疗的OR为1.84(95%CI 1.67-2.02),放疗OR为1.53(95%CI 1.32-1.78),ADT OR为2.66(95%CI 2.10-3.36),ADT+放疗OR为2.56(95%CI 2.23-2.93)。

临床怎么用

  • 临床决策需关注社会经济地位和医院类型对局限性前列腺癌治疗选择的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe the patterns of care and factors associated with treatment uptake of localised prostate cancer, using the bi-national Prostate Cancer Outcomes Registry-Australia and New Zealand (PCOR-ANZ) database. METHODS: Data for 36 504 patients, diagnosed between 2015 and 2018, from New Zealand and seven Australian jurisdictions were evaluated. Multinomial logistic regression was performed to identify factors associated with the likelihood of receiving no active treatment, radiotherapy (RT), androgen deprivation therapy (ADT) and combined ADT + RT, compared to radical prostatectomy (RP). RESULTS: The most common disease risk group and treatment were intermediate-risk disease (49.2%) and RP (40.3%). Men with low-risk disease were mostly managed by no active treatment (81.5%). Compared to men treated with RP, the likelihood of receiving other treatments was higher in residents from regional areas, those from lower socio-economic status (SES) areas and those diagnosed at regional or public hospitals. Being in the lowest SES group was associated with an odds ratio (OR) of 1.84, (95% confidence interval [CI] 1.67-2.02) of having no active treatment, an OR of 1.53 (95% CI 1.32-1.78) for RT, an OR of 2.66 (95% CI 2.10-3.36) for ADT and an OR of 2.56 (95% CI 2.23-2.93) for ADT + RT. CONCLUSIONS: Factors related to SES and hospital provider were associated with treatment choices in localised prostate cancer patients, independent of their age or disease risk classification.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Chiam K, Bang A, Nair-Shalliker V, et al. Treatment variations in localised prostate cancer in Australia and New Zealand: a registry study. BJU Int. 2025. PMID: 40844873. doi:10.1111/bju.16896

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。